Stockreport

Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema [Yahoo! Finance]

Astria Therapeutics, Inc.  (ATXS) 
PDF BOSTON, February 27, 2025 BUSINESS WIRE Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic [Read more]